The Role of Oxidized Cholesterol in Diabetes-Induced Lysosomal Dysfunction in the Brain

Molecular Neurobiology

Volumn 53, Issue 4, 2016, Pages 2287-2296

  Sims Robinson, Catrina ^a,b   Bakeman, Anna ^a   Rosko, Andrew ^a   Glasser, Rebecca ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Brain; Cathepsin D; Central nervous system; Cholesterol; Lysosome; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACTIN; BETA N ACETYLHEXOSAMINIDASE A; CATHEPSIN D; CHOLESTEROL; GLUCOSE; LYSOSOME ENZYME; OXIDIZED CHOLESTEROL; PIOGLITAZONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DISEASE; CELL MIGRATION; CELL PH; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME MECHANISM; HIPPOCAMPUS; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN SENSITIVITY; LYSOSOME STORAGE DISEASE; MOUSE; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TRANSPORT; ANIMAL; BRAIN; COMPLICATION; ENZYMOLOGY; FLUORESCENCE; INTRACELLULAR MEMBRANE; LYSOSOME; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PH; PHENOTYPE; STAINING;

ANIMALS; BRAIN; CATHEPSIN D; CEREBRAL CORTEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FLUORESCENCE; GLUCOSE; HEXOSAMINIDASE A; HIPPOCAMPUS; HYDROGEN-ION CONCENTRATION; HYPERGLYCEMIA; INTRACELLULAR MEMBRANES; LYSOSOMES; MICE; OXIDATION-REDUCTION; PHENOTYPE; STAINING AND LABELING; THIAZOLIDINEDIONES;

EID: 84929427648     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9207-1     Document Type: Article

References (60)

1. Li L, Holscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56(2):384–402. doi:10.1016/j.brainresrev.2007.09.001
2. Biessels GJ, ter Laak MP, Hamers FP, Gispen WH (2002) Neuronal Ca2+ disregulation in diabetes mellitus. Eur J Pharmacol 447(2-3):201–209
3. Franke K, Gaser C, Manor B, Novak V (2013) Advanced BrainAGE in older adults with type 2 diabetes mellitus. Front Aging Neurosci 5:90. doi:10.3389/fnagi.2013.00090
4. Zhang L, Sheng R, Qin Z (2009) The lysosome and neurodegenerative diseases. Acta Biochim Biophys Sin 41(6):437–445
5. Cuervo AM, Dice JF (2000) When lysosomes get old. Exp Gerontol 35(2):119–131
6. Nixon RA, Yang DS, Lee JH (2008) Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 4(5):590–599
7. Tagami S, Inokuchi Ji J, Kabayama K, Yoshimura H, Kitamura F, Uemura S, Ogawa C, Ishii A et al (2002) Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem 277(5):3085–3092. doi:10.1074/jbc.M103705200
8. Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, Kono M, Tsuji S et al (2003) Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A 100(6):3445–3449. doi:10.1073/pnas.0635898100
9. Llorente L, De La Fuente H, Richaud-Patin Y, Alvarado-De La Barrera C, Diaz-Borjon A, Lopez-Ponce A, Lerman-Garber I, Jakez-Ocampo J (2000) Innate immune response mechanisms in non-insulin dependent diabetes mellitus patients assessed by flow cytoenzymology. Immunol Lett 74(3):239–244
10. Duckworth WC, Hamel FG, Peavy DE (1988) Hepatic metabolism of insulin. Am J Med 85(5A):71–76
11. Valera Mora ME, Scarfone A, Calvani M, Greco AV, Mingrone G (2003) Insulin clearance in obesity. J Am Coll Nutr 22(6):487–493
12. Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45(12):1661–1669
13. Kahn CR, Chen L, Cohen SE (2000) Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106(11):1305–1307. doi:10.1172/JCI11705
14. Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL, Beckett TL, Murphy MP et al (2012) Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer’s disease. J Alzheimer’s Dis: JAD 30(4):943–961. doi:10.3233/JAD-2012-111661
15. Liu C, Feng T, Zhu N, Liu P, Han X, Chen M, Wang X, Li N et al (2015) Identification of a novel selective agonist of PPARgamma with no promotion of adipogenesis and less inhibition of osteoblastogenesis. Sci Reports 5:9530. doi:10.1038/srep09530
16. Hanyu H, Sato T, Sakurai H, Iwamoto T (2010) The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer’s disease. J Am Geriatr Soc 58(5):1000–1001. doi:10.1111/j.1532-5415.2010.02841.x
17. Chiang MC, Chern Y, Huang RN (2012) PPARgamma rescue of the mitochondrial dysfunction in Huntington’s disease. Neurobiol Dis 45(1):322–328. doi:10.1016/j.nbd.2011.08.016
18. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351(11):1106–1118. doi:10.1056/NEJMra041001
19. Saltiel AR (2001) New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104(4):517–529
20. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331(18):1188–1193. doi:10.1056/NEJM199411033311803
21. Mauvais-Jarvis F, Kahn CR (2000) Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: what can we learn from transgenic and knockout mice? Diabetes Metabolism 26(6):433–448
22. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD (1994) Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 43(2):204–211
23. Bowen L, Stein PP, Stevenson R, Shulman GI (1991) The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metab Clin Exp 40(10):1025–1030
24. 2014 annual meetings (2014) Annals of neurology 76(Suppl 18):S1–S254. doi:10.1002/ana.24247
25. Harris MI (1991) Hypercholesterolemia in diabetes and glucose intolerance in the U.S. population. Diabetes Care 14(5):366–374
26. Simonen PP, Gylling HK, Miettinen TA (2002) Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care 25(9):1511–1515
27. Miettinen TA, Gylling H, Tuominen JA, Simonen P, Koivisto V (2004) Absorption and synthesis of cholesterol in patients with type 1 and type2 diabetes mellitus. Duodecim 120(6):721–723
28. Murakami H, Tamasawa N, Matsui J, Yasujima M, Suda T (2000) Plasma oxysterols and tocopherol in patients with diabetes mellitus and hyperlipidemia. Lipids 35(3):333–338
29. Ferderbar S, Pereira EC, Apolinario E, Bertolami MC, Faludi A, Monte O, Calliari LE, Sales JE et al (2007) Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus. Diabetes Metab Res Rev 23(1):35–42. doi:10.1002/dmrr.645
30. Roussi S, Gosse F, Aoude-Werner D, Zhang X, Marchioni E, Geoffroy P, Miesch M, Raul F (2007) Mitochondrial perturbation, oxidative stress and lysosomal destabilization are involved in 7beta-hydroxysitosterol and 7beta-hydroxycholesterol triggered apoptosis in human colon cancer cells. Apoptosis: An Int J programmed Cell Death 12(1):87–96. doi:10.1007/s10495-006-0485-y
31. Li W, Dalen H, Eaton JW, Yuan XM (2001) Apoptotic death of inflammatory cells in human atheroma. Arterioscler Thromb Vasc Biol 21(7):1124–1130
32. Terman A, Brunk UT (2006) Oxidative stress, accumulation of biological ‘garbage’, and aging. Antioxidants Redox Signal 8(1-2):197–204. doi:10.1089/ars.2006.8.197
33. Belfiore F, Rabuazzo AM, Iannello S, Campione R, Vasta D (1985) Cathepsin D and other hydrolases in the kidney of streptozotocin-diabetic mice. Possible relevance to microangiopathy. Hormone Metab Res 17(9):435–437. doi:10.1055/s-2007-1013570
34. Chua BH, Long WM, Lautensack N, Lins JA, Morgan HE (1983) Effects of diabetes on cardiac lysosomes and protein degradation. Am J Physiol 245(1):C91–100
35. Knas M, Karaszewska K, Szajda SD, Zarzycki W, Dudzik D, Zwierz K (2006) Saliva of patients with Type 1 diabetes: effect of smoking on activity of lysosomal exoglycosidases. Oral Dis 12(3):278–282. doi:10.1111/j.1601-0825.2005.01190.x
36. Tiribuzi R, Orlacchio A, Crispoltoni L, Maiotti M, Zampolini M, De Angeliz M, Mecocci P, Cecchetti R et al (2011) Lysosomal beta-galactosidase and beta-hexosaminidase activities correlate with clinical stages of dementia associated with Alzheimer’s disease and type 2 diabetes mellitus. J Alzheimer’s Dis: JAD 24(4):785–797. doi:10.3233/JAD-2011-100525
37. Sims-Robinson C, Zhao S, Hur J, Feldman EL (2012) Central nervous system endoplasmic reticulum stress in a murine model of type 2 diabetes. Diabetologia 55(8):2276–2284. doi:10.1007/s00125-012-2573-6
38. Zhao Q, Niu Y, Matsumoto K, Tsuneyama K, Tanaka K, Miyata T, Yokozawa T (2012) Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain. BMC Complement Alternativ Med 12:188. doi:10.1186/1472-6882-12-188
39. Zhao Q, Matsumoto K, Tsuneyama K, Tanaka K, Li F, Shibahara N, Miyata T, Yokozawa T (2011) Diabetes-induced central cholinergic neuronal loss and cognitive deficit are attenuated by tacrine and a Chinese herbal prescription, kangen-karyu: elucidation in type 2 diabetes db/db mice. J Pharmacol Sci 117(4):230–242
40. Stranahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM, Mattson MP (2008) Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci 11(3):309–317. doi:10.1038/nn2055
41. Ramos-Rodriguez JJ, Ortiz O, Jimenez-Palomares M, Kay KR, Berrocoso E, Murillo-Carretero MI, Perdomo G, Spires-Jones T et al (2013) Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology 38(11):2462–2475. doi:10.1016/j.psyneuen.2013.05.010
42. Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, Hori T (2002) Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 113(3):607–615
43. Huang S, Wang Y, Gan X, Fang D, Zhong C, Wu L, Hu G, Sosunov AA et al (2014) Drp1-Mediated Mitochondrial Abnormalities Link to Synaptic Injury in Diabetes Model. Diabetes. doi:10.2337/db14-0758
44. Dinel AL, Andre C, Aubert A, Ferreira G, Laye S, Castanon N (2011) Cognitive and emotional alterations are related to hippocampal inflammation in a mouse model of metabolic syndrome. PLoS One 6(9), e24325. doi:10.1371/journal.pone.0024325
45. Kim B, Backus C, Oh S, Hayes JM, Feldman EL (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150(12):5294–5301. doi:10.1210/en.2009-0695
46. Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM, Lastoskie C, Feldman EL (2007) Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 148(2):548–558. doi:10.1210/en.2006-0073
47. Kim B, Sullivan KA, Backus C, Feldman EL (2011) Cortical neurons develop insulin resistance and blunted Akt signaling: a potential mechanism contributing to enhanced ischemic injury in diabetes. Antioxidants Redox Signal 14(10):1829–1839. doi:10.1089/ars.2010.3816
48. Antunes F, Cadenas E, Brunk UT (2001) Apoptosis induced by exposure to a low steady-state concentration of H2O2 is a consequence of lysosomal rupture. Biochem J 356(Pt 2):549–555
49. Li W, Yuan XM, Olsson AG, Brunk UT (1998) Uptake of oxidized LDL by macrophages results in partial lysosomal enzyme inactivation and relocation. Arterioscler Thromb Vasc Biol 18(2):177–184
50. Cataldo AM, Hamilton DJ, Nixon RA (1994) Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res 640(1-2):68–80
51. Cataldo AM, Paskevich PA, Kominami E, Nixon RA (1991) Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc Natl Acad Sci U S A 88(24):10998–11002
52. Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, Frey W 2nd, Haase AT (1991) Neuropathological changes in scrapie and Alzheimer’s disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol 65(9):4759–4768
53. Schwagerl AL, Mohan PS, Cataldo AM, Vonsattel JP, Kowall NW, Nixon RA (1995) Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J Neurochem 64(1):443–446
54. Tanabe A, Matsuda M, Fukuhara A, Miyata Y, Komuro R, Shimomura I, Tojo H (2009) Obesity causes a shift in metabolic flow of gangliosides in adipose tissues. Biochem Biophys Res Commun 379(2):547–552. doi:10.1016/j.bbrc.2008.12.086
55. Nakamura Y, Takeda M, Suzuki H, Hattori H, Tada K, Hariguchi S, Hashimoto S, Nishimura T (1991) Abnormal distribution of cathepsins in the brain of patients with Alzheimer’s disease. Neurosci Lett 130(2):195–198
56. Hamed EA, Zakary MM, Abdelal RM, Abdel Moneim EM (2011) Vasculopathy in type 2 diabetes mellitus: role of specific angiogenic modulators. J Physiol Biochem 67(3):339–349. doi:10.1007/s13105-011-0080-8
57. Zaidi N, Maurer A, Nieke S, Kalbacher H (2008) Cathepsin D: a cellular roadmap. Biochem Biophys Res Commun 376(1):5–9. doi:10.1016/j.bbrc.2008.08.099
58. Hwang JJ, Lee SJ, Kim TY, Cho JH, Koh JY (2008) Zinc and 4-hydroxy-2-nonenal mediate lysosomal membrane permeabilization induced by H2O2 in cultured hippocampal neurons. J Neurosci: Off J Soc Neurosci 28(12):3114–3122. doi:10.1523/JNEUROSCI.0199-08.2008
59. Kagedal K, Johansson U, Ollinger K (2001) The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stress. FASEB J: Off Publ Fed Am Soci Exp Biol 15(9):1592–1594
60. Moheimani F, Kim CH, Rahmanto AS, van Reyk DM, Davies MJ (2012) Inhibition of lysosomal function in macrophages incubated with elevated glucose concentrations: a potential contributory factor in diabetes-associated atherosclerosis. Atherosclerosis 223(1):144–151. doi:10.1016/j.atherosclerosis.2012.04.026